Curious how the healthcare provisions in the Inflation Reduction Act will impact your business? Start with this booklet by key experts from PRECISIONvalue where 5 experts weigh in on how the Inflation Reduction Act will affect payers in addition to 2023 trends, events, and developments in the payer world. Download the booklet.
Data and analytics can help drive and inform launch preparations and support efforts to achieve launch excellence through realistic goal-setting and risk mitigation. PRECISIONadvisors works with manufacturers, helping them make key decisions—related to product positioning, go-to-market strategy, and customer engagement across payers, providers, prescribers, and patients—through data- and analytics-driven insights. Learn how an integrated data-driven approach can set realistic goals and de-risk your launch.
Interested in learning more about several legislative events shaping the managed care landscape in 2022 and beyond? Check out this insightful white paper, based on our recent webinar, which features insights from PRECISIONvalue’s expert Access Experience Team on various legislative proposals and payers’ potential responses to regulatory changes.
Oral chemotherapeutic agents comprise 25% to 35% of oncology drugs in development. They are an increasingly vital component of anticancer treatment and are anticipated to play an even larger role in the longer term.
Care management is a broad term often encompassing disease management, case management, and utilization management functions. The need for strong care management capabilities is fundamental to the success of value-based care, team-based care, and population health management.
In 2021, COVID-19 and its ongoing impact on the healthcare, scientific, political, and social climate continued to be the dominant transformative lens through which we view trends in the following areas: healthcare costs, clinical practice and scientific innovation, US healthcare policy, value-based care, and pandemic/endemic management.
In this white paper, we explore the results of an exclusive Precision Value & Health survey on how payers and providers are adapting to—and supporting—the delivery of value-based care in an evolving oncology landscape.
Increasingly, stakeholders across the healthcare continuum are recognizing the importance of social determinants of health (SDOH) on outcomes and quality of life. In this white paper from Precision’s Maureen Hennessey, we use the results of a 2019 PRECISIONvalue survey and a subsequent 2020 post-onset of COVID-19 survey to evaluate perspectives on SDOH and assess the progress of programs to address SDOH.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
